Zhen J, Simoneau M, Sharma P, Germain P, Watier-Levesque P, Othman A
J Can Assoc Gastroenterol. 2024; 7(6):423-430.
PMID: 39679104
PMC: 11638002.
DOI: 10.1093/jcag/gwae029.
Welzel T, Zapf B, Klotsche J, Satirer O, Benseler S, Kuemmerle-Deschner J
J Clin Med. 2024; 13(8).
PMID: 38673592
PMC: 11050771.
DOI: 10.3390/jcm13082319.
Zucchi D, Cardelli C, Elefante E, Tani C, Mosca M
J Clin Med. 2023; 12(9).
PMID: 37176788
PMC: 10178979.
DOI: 10.3390/jcm12093348.
Omair M, Alkhelb S, Ezzat S, Boudal A, Bedaiwi M, Almaghlouth I
Open Access Rheumatol. 2022; 14:231-242.
PMID: 36276408
PMC: 9586712.
DOI: 10.2147/OARRR.S284757.
Burrone M, Mazzoni M, Naddei R, Pistorio A, Spelta M, Scala S
Pediatr Rheumatol Online J. 2022; 20(1):80.
PMID: 36071444
PMC: 9450438.
DOI: 10.1186/s12969-022-00739-x.
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Ziesenitz V, Welzel T, van Dyk M, Saur P, Gorenflo M, van den Anker J
Paediatr Drugs. 2022; 24(6):603-655.
PMID: 36053397
PMC: 9592650.
DOI: 10.1007/s40272-022-00514-1.
Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood.
Welzel T, Benseler S, Kuemmerle-Deschner J
Front Immunol. 2021; 12:516427.
PMID: 33868220
PMC: 8044959.
DOI: 10.3389/fimmu.2021.516427.
Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T, Winskill C, Zhang N, Woerner A, Pfister M
Pediatr Rheumatol Online J. 2021; 19(1):46.
PMID: 33766063
PMC: 7995584.
DOI: 10.1186/s12969-021-00514-4.
Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
Nam B, Koo B, Lee T, Shin J, Kim J, Lee S
BMC Musculoskelet Disord. 2021; 22(1):140.
PMID: 33541326
PMC: 7860220.
DOI: 10.1186/s12891-020-03941-8.
Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?.
Welzel T, Kuemmerle-Deschner J
J Clin Med. 2021; 10(1).
PMID: 33401496
PMC: 7794776.
DOI: 10.3390/jcm10010128.
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
van de Laar C, Oude Voshaar M, Fakhouri W, Zaremba-Pechmann L, De Leonardis F, de la Torre I
Clinicoecon Outcomes Res. 2020; 12:213-222.
PMID: 32346301
PMC: 7167259.
DOI: 10.2147/CEOR.S231558.
Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice.
Taylor P, Alten R, Gomez Reino J, Caporali R, Bertin P, Sullivan E
Patient Prefer Adherence. 2018; 12:2007-2014.
PMID: 30323570
PMC: 6179241.
DOI: 10.2147/PPA.S170054.
Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry.
Strand V, Miller P, Williams S, Saunders K, Grant S, Kremer J
Rheumatol Ther. 2017; 4(2):489-502.
PMID: 28831751
PMC: 5696290.
DOI: 10.1007/s40744-017-0078-y.
Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry.
Cardenas M, de la Fuente S, Castro-Villegas M, Romero-Gomez M, Ruiz-Vilchez D, Calvo-Gutierrez J
Rheumatol Int. 2016; 36(12):1627-1632.
PMID: 27778067
DOI: 10.1007/s00296-016-3583-3.
Interface Management between General Practitioners and Rheumatologists-Results of a Survey Defining a Concept for Future Joint Recommendations.
Puchner R, Edlinger M, Mur E, Eberl G, Herold M, Kufner P
PLoS One. 2016; 11(1):e0146149.
PMID: 26741702
PMC: 4704827.
DOI: 10.1371/journal.pone.0146149.
Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry.
Cardenas M, de la Fuente S, Font P, Castro-Villegas M, Romero-Gomez M, Ruiz-Vilchez D
Rheumatol Int. 2015; 36(2):231-41.
PMID: 26494567
DOI: 10.1007/s00296-015-3374-2.
Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations.
Koike T
J Orthop Sci. 2015; 20(6):951-7.
PMID: 26404390
PMC: 4653232.
DOI: 10.1007/s00776-015-0766-9.
Power of national economy, disease control and employment status in patients with RA-an analytical multi-site ecological study.
Pieringer H, Puchner R, Pohanka E, Danninger K
Clin Rheumatol. 2015; 35(2):461-5.
PMID: 25805536
DOI: 10.1007/s10067-015-2918-x.
Management of juvenile idiopathic arthritis: hitting the target.
Hinze C, Gohar F, Foell D
Nat Rev Rheumatol. 2015; 11(5):290-300.
PMID: 25561365
DOI: 10.1038/nrrheum.2014.212.
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.
Choy E, Ganeshalingam K, Semb A, Szekanecz Z, Nurmohamed M
Rheumatology (Oxford). 2014; 53(12):2143-54.
PMID: 24907149
PMC: 4241890.
DOI: 10.1093/rheumatology/keu224.